This year is the last year for the transformation of traditional Chinese medicine decoction pieces GMP. It is imperative to update the production technology of decoction pieces. Many leading pharmaceutical and packaging equipment companies are therefore well prepared to meet the new round of procurement boom.
On the one hand, the intention of the Chinese medicine manufacturers to update their equipment is constantly rising, and many people in the industry also applaud the company's equipment. On the other hand, it is a reminder given by industry experts that investment in GMP processing and production equipment must be discreet.
Since the 1960s, no fundamental changes have taken place in the production methods and transaction forms of the Chinese Herbal Pieces industry. The backward production process, imperfect product quality standards and many other factors have constrained the large circulation of the development of the decoction pieces. Therefore, we must fundamentally resolve this bottleneck. Only the technological innovation in the processing technology of traditional Chinese medicine decoction pieces will be continuously introduced to make new products. Pieces of processing as soon as possible to embark on the scale of intensification.
Experts in the industry believe that from the perspective of the overall market, the market sales volume of TCM decoction pieces has been declining over the years. The market capacity and prescription drugs have been shrinking. The current production capacity of decoction processing is far greater than the market sales, and there is potential for overheated investment. The danger of blind investment. Although investment in GMP production equipment of traditional Chinese medicine decoction pieces can greatly promote the development of traditional Chinese medicine decoction pieces processing industry, blindly encouraging investment if it is not properly guided in this area will inevitably result in a fatal blow to the inherently insufficient Chinese herbal medicine processing industry and increase investment. The risk to the fund has an adverse effect on the full implementation of the emerging GMP certified processing and production projects. Therefore, in the face of the current enthusiasm for the Chinese medicine industry's enthusiasm in investing in GMP processing equipment, the classification guidance should be conducted to increase the investor’s financial security and maximize the investment benefits.
In addition, in addition to the introduction of new equipment, it is more important for TCM decoction pieces companies to learn advanced technologies from Chinese medicine companies in Hong Kong, Taiwan, Japan and Singapore. These companies have fundamentally solved the problems that have not been solved by a series of traditional Chinese medicine pieces, such as the inconsistent quality of traditional Chinese medicine pieces, the serious secondary pollution in the sales process, and the inconvenience and time-consuming work of traditional Chinese medicine pieces.
On the one hand, the intention of the Chinese medicine manufacturers to update their equipment is constantly rising, and many people in the industry also applaud the company's equipment. On the other hand, it is a reminder given by industry experts that investment in GMP processing and production equipment must be discreet.
Since the 1960s, no fundamental changes have taken place in the production methods and transaction forms of the Chinese Herbal Pieces industry. The backward production process, imperfect product quality standards and many other factors have constrained the large circulation of the development of the decoction pieces. Therefore, we must fundamentally resolve this bottleneck. Only the technological innovation in the processing technology of traditional Chinese medicine decoction pieces will be continuously introduced to make new products. Pieces of processing as soon as possible to embark on the scale of intensification.
Experts in the industry believe that from the perspective of the overall market, the market sales volume of TCM decoction pieces has been declining over the years. The market capacity and prescription drugs have been shrinking. The current production capacity of decoction processing is far greater than the market sales, and there is potential for overheated investment. The danger of blind investment. Although investment in GMP production equipment of traditional Chinese medicine decoction pieces can greatly promote the development of traditional Chinese medicine decoction pieces processing industry, blindly encouraging investment if it is not properly guided in this area will inevitably result in a fatal blow to the inherently insufficient Chinese herbal medicine processing industry and increase investment. The risk to the fund has an adverse effect on the full implementation of the emerging GMP certified processing and production projects. Therefore, in the face of the current enthusiasm for the Chinese medicine industry's enthusiasm in investing in GMP processing equipment, the classification guidance should be conducted to increase the investor’s financial security and maximize the investment benefits.
In addition, in addition to the introduction of new equipment, it is more important for TCM decoction pieces companies to learn advanced technologies from Chinese medicine companies in Hong Kong, Taiwan, Japan and Singapore. These companies have fundamentally solved the problems that have not been solved by a series of traditional Chinese medicine pieces, such as the inconsistent quality of traditional Chinese medicine pieces, the serious secondary pollution in the sales process, and the inconvenience and time-consuming work of traditional Chinese medicine pieces.